The effect of a fixed-dose combination drug strategy ('polypill') on patients' adherence to medication was analysed in a series of 2,004 individuals with, or at high risk of, cardiovascular disease in the UMPIRE study. The polypill improved adherence by >20%, but the reduction in blood-pressure and cholesterol levels was modest.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).
Beaglehole, R. & Bonita, R. Global public health: a scorecard. Lancet 372, 1988–1996 (2008).
Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 378, 1231–1243 (2011).
Mendis, S. et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull. World Health Organ. 85, 279–288 (2007).
Chapman, R. H. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 165, 1147–1152 (2005).
Jansa, M. et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions: a cross-sectional study in a tertiary hospital. Patient Educ. Couns. 81, 161–168 (2010).
Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
Elley, C. R. et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS ONE 7, e52145 (2012).
Sanz, G. & Fuster, V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J. Med. 79, 683–688 (2012).
Sanz, G. et al. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug: study design and objectives. Am. Heart J. 162, 811–817 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests. G. Sanz and V. Fuster are involved in designing and trialling a polypill with Ferrer Internacional (Barcelona, Spain).
PowerPoint slides
Rights and permissions
About this article
Cite this article
Sanz, G., Fuster, V. Polypills for cardiovascular prevention: a step forward?. Nat Rev Cardiol 10, 683–684 (2013). https://doi.org/10.1038/nrcardio.2013.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.157
This article is cited by
-
The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome
Cardiovascular Drugs and Therapy (2023)
-
Top 10 cardiovascular therapies and interventions for the next decade
Nature Reviews Cardiology (2014)